Table 1

HER-2/neu amplification status by multiplex ligation-dependent probe amplification (MLPA) of 42 breast cancer patients in undissected sections and after manual and laser microdissection, in comparison with in situ hybridization and immunohistochemistry.



MLPA

Case number
 IHC
 ISH
 Undissected
 Manual MD
 Laser MD
 DCIS
 Tumor %
1
 0
 NA
 1
 1
 1
 Yes
 30
2
 0
 NA
 1
 1
 1
30
3
 0
 NA
 1
 1
 1
 Yes
 10
4
 2
 NA
 1
 1
 1
10
5
 2
 NA
 1
 1
 1
 Yes
 70
6
 2
 NA
 1
 1
 2
 Yes
 70
7
 2
 NA
 1
 1
 1
50
8
 2
 NA
 1
 1
 1
70
9
 2
 NA
 1
 1
 1
70
10
 2
 NA
 1
 1
 1
60
11
 2
 NA
 1
 1
 1
30
12
 2
 NA
 1
 1
 1
60
13
 1
 LA
 2
 2
 2
70
14
 2
 A
 2
 3
 3
80
15
 2
 A
 2
 2
 3
 Yes
 80
16
 3
 A
 2
 2
 3
80
17
 2
 LA
 2
 2
 3
80
18
 0
 NA
 2
 1
 1
 Yes
 90
19
 0
 NA
 2
 1
 1
80
20
 1
 A
 2
 3
 3
70
21
 1
 LA
 2
 3
 2
 Yes
 50
22
 1
 NA
 2
 2
 1
 Yes
 80
23
 1
 NA
 2
 1
 1
 Yes
 10
24
 1
 NA
 2
 1
 1
 Yes
 60
25
 0
 NA
 3
 1
 1
60
26
 0
 NA
 3
 1
 1
80
27
 1
 A
 3
 3
 3
70
28
 1
 NA
 3
 3
 3
 Yes
 30
29
 3
 A
 3
 3
 3
50
30
 1
 A
 3
 3
 3
80
31
 2
 A
 3
 3
 3
 Yes
 70
32
 3
 A
 3
 3
 3
 Yes
 80
33
 3
 A
 3
 3
 3
20
34
 3
 A
 3
 3
 3
70
35
 3
 A
 3
 3
 3
80
36
 3
 A
 3
 3
 3
70
37
 3
 A
 3
 3
 3
30
38
 3
 A
 3
 3
 3
70
39
 3
 A
 3
 3
 3
60
40
 2
 A
 3
 3
 3
 Yes
 40
41
 3
 A
 3
 3
 3
 Yes
 20
42
 3
 A
 3
 3
 3
10

IHC = immunohistochemistry (Hercep test), ISH = in situ hybridization, NA = non-amplified, LA = low-level amplified, A = amplified, MD = microdissection, DCIS = ductal carcinoma in situ

Moelans et al. BMC Cancer 2009 9:4   doi:10.1186/1471-2407-9-4